uniQure N.V. (QURE) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $24.60: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 2.59; Below-average business quality.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate... Read more
Sell if holding. Engine safety override at $24.60: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 2.59; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.2/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 70d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — uniQure N.V.
Latest news
- 10 Health Care Stocks Whale Activity In Today's Session — benzinga May 12, 2026 neutral
- 'Makary's Time Atop FDA Over, Diamantas Named Acting Commissioner' - Politico — benzinga May 12, 2026 neutral
- 'Trump Approves Plan To Fire FDA Commissioner Marty Makary, Sources Say' - CBS — benzinga May 11, 2026 neutral
- Watching ClearPoint Neuro, uniQure; Shares Spike Higher After WSJ Reports "Trump Planning to Fire FDA Commissioner Marty — benzinga May 8, 2026 positive
- HC Wainwright & Co. Maintains Buy on uniQure, Lowers Price Target to $50 — benzinga May 6, 2026 neutral
Generated 2026-05-20T22:01:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
5 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 9.3% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $24.60: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 2.59; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $22.88. Score 5.2/10, moderate confidence.
Take-profit target: $33.93 (+37.9% upside). Prior stop was $22.88. Stop-loss: $22.88.
Quality below floor (1.8 < 4.0).
uniQure N.V. trades at a P/E of N/A (forward -8.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
21 analysts cover QURE with a consensus score of 4.0/5. Average price target: $39.
What does uniQure N.V. do?uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States....
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.